A standard cholesterol result can be reassuring without answering every question about inherited cardiovascular risk. Lipoprotein(a), usually written Lp(a), is a separate blood measurement. A raised level can help explain risk in someone who exercises regularly, has a favourable routine lipid profile, or has a family history of heart disease at a young age.
The Wellness offers doctor-led health assessments and blood testing in London. An Lp(a) discussion is most useful when it connects your result with your wider cardiovascular history and a clear prevention plan. The team can confirm whether the test is appropriate, the exact scope of testing, the review arrangements and the fee before booking.
Enquire about Lp(a) testing and a cardiovascular risk review
What lipoprotein(a) adds to a cholesterol assessment
Lipoproteins carry fats through the blood. Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a). Its concentration is largely inherited. Higher levels are associated with a greater risk of cardiovascular disease, including coronary heart disease and stroke, and with aortic valve disease.
A routine lipid panel and an Lp(a) test answer different questions. Total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides remain important. They do not reliably tell you whether your Lp(a) is raised. Someone can have an apparently favourable LDL cholesterol result and still have an inherited risk factor that deserves attention.
That does not make Lp(a) a diagnosis of a blocked artery. It is a risk marker, not a scan, a prediction of the date of a heart attack or a verdict on your future. Its value lies in helping the doctor judge how actively to address the risks that can be changed.
Why family history matters even when you feel well
A history of early heart disease in a parent, brother or sister can change the interpretation of an otherwise unremarkable health assessment. The age at which the event happened matters, as does the nature of the event. A heart attack, stroke, coronary procedure or diagnosed inherited cholesterol condition is more useful information than a general recollection that heart problems run in the family.
HEART UK identifies personal or family premature cardiovascular disease, familial hypercholesterolaemia and close relatives of people with significantly raised Lp(a) among the reasons to consider testing. Its patient guidance also discusses calcific aortic valve disease and situations where a person's overall cardiovascular risk is uncertain.
A clinician can bring these details together without assuming every family shares the same risk. A raised result does not mean that a relative will necessarily develop disease. It may, however, provide a reason for the family to discuss appropriate assessment with their own healthcare professionals.
What the 2026 guidance changes
The American Heart Association's summary of the 2026 ACC/AHA dyslipidaemia guideline recommends measuring Lp(a) at least once in adulthood as part of improved risk assessment. This is a broader testing approach than descriptions that reserve the measurement only for selected high-risk patients.
UK guidance and access routes should still be described accurately. HEART UK's May 2026 patient guidance sets out particular groups in whom measurement is recommended and explains specialist lipid-clinic input. A US guideline is useful evidence; it is not a statement that every UK health check already includes the test or that every person needs the same treatment afterwards.
For a London assessment, the practical question is what knowing your Lp(a) would change. An informed review can identify inherited risk that a routine panel misses while avoiding repeated testing that does not add useful information. Inclusion in a particular package should be confirmed rather than assumed from its name.
Reading the number starts with the units
Lp(a) reports may use nmol/L, mg/dL or mg/L. These are not interchangeable labels. A number without its unit is incomplete, and a result from another country should be read from the original laboratory report rather than a remembered figure.
HEART UK recommends measurement in nmol/L and describes risk categories using that unit. Other sources and laboratories may present different thresholds or reporting conventions. The doctor should explain which framework is being used and how it relates to the method and unit on your report.
There is no need to force two reports into a single number using a casual online conversion. Keeping the original result, units, laboratory reference information and test date allows a more careful comparison. A threshold is an aid to interpretation, not a replacement for your history or a reason to change medicines on your own.
A result near a category boundary should not be treated as though your risk changes abruptly at one exact decimal place. Cardiovascular prevention is based on the wider picture: blood pressure, smoking, diabetes, kidney disease, cholesterol, existing vascular disease and family history all matter.
Arrange a doctor-led review of your cardiovascular results
What happens after a raised Lp(a) result
The first task is to understand the result in context. A doctor can review whether you already have cardiovascular disease, how other risk factors are being managed and whether lipid-specialist advice would help. Existing treatment and previous adverse effects are part of that conversation.
Lp(a) is largely genetic and is usually not substantially reduced by changes in diet or exercise. This should not be heard as a reason to give up on prevention. Healthy eating, regular activity, not smoking and addressing blood pressure can still reduce overall cardiovascular risk, even when the Lp(a) number itself changes little.
LDL and non-HDL cholesterol remain important treatment targets. A doctor may discuss cholesterol-lowering treatment in light of your total risk, rather than attempting to treat a single laboratory flag in isolation. A raised Lp(a) does not automatically identify one medicine, dose or target that is right for everyone.
HEART UK notes that statins do not lower the amount of Lp(a), but they can lower LDL and non-HDL cholesterol. A result should therefore not be used as a reason to stop a prescribed statin. The purpose of treatment is reducing the risk of cardiovascular events, not making every laboratory measurement move in the same direction.
A clear plan is more useful than an annual repeat by default
Lp(a) usually remains relatively stable because much of its concentration is inherited. Many people will not need it measured repeatedly after an informative result. The 2026 US recommendation is testing at least once in a lifetime, not an instruction to add it to every annual blood panel.
There are circumstances in which a clinician may want to reassess the interpretation or measurement. HEART UK describes secondary influences including some kidney conditions and hypothyroidism. The clinical history and the reason for the original test help decide whether another measurement would add anything.
Follow-up can instead focus on what changes management: agreed cholesterol targets, blood pressure, smoking cessation, diabetes care, medicine tolerance and the next review date. When the plan names the next action and the person responsible for reviewing it, a screening result becomes part of continuing care.
For someone travelling often or using more than one healthcare system, a concise record is particularly useful. It can include the original Lp(a) report, relevant family history, current medicines and the agreed prevention plan. Further sharing with your usual doctor should be arranged with your permission.
Preparing for the blood test
Lp(a) is measured from a blood sample. The preparation instructions should relate to the actual tests being taken at the same appointment. Different sources and laboratories describe different fasting arrangements, and another component of a combined panel may be the reason fasting is requested.
The team can confirm the instructions for your appointment, including whether fasting is needed and what to do about your usual medicines. Do not stop prescribed treatment or begin a prolonged fast solely because of general information online. If diabetes, pregnancy, fainting during blood tests or a difficult blood draw affects the appointment, the team should know before you attend.
A full medication and supplement record helps interpretation. Previous lipid results and the original report of an earlier Lp(a) test may save an unnecessary repeat. Recent illness or an important change in health is also relevant to the doctor's assessment.
The blood draw itself may cause brief discomfort or bruising. The expected result timing and review route should be confirmed for your test rather than inferred from a different blood panel or a previous appointment.
When a specialist review may add value
Lipid-specialist advice may help when inherited risk is substantial, cardiovascular disease has occurred early or repeatedly, cholesterol remains difficult to control, or the result needs interpretation alongside a complex medical history. The decision follows the individual assessment rather than a promise that every raised result needs a procedure.
Research into treatments that directly lower Lp(a) is active. A large reduction in a biomarker in a study is not, on its own, proof that the treatment prevents heart attacks or strokes. The evidence for clinical outcomes, the treatment's regulatory status and its suitability for an individual need separate consideration.
This article does not promise access to an experimental treatment or describe a specialist drug as routinely available from the clinic. Where further care is appropriate, the useful next step is a clear explanation of the reason for referral and the information the specialist will need.
Discuss inherited cardiovascular risk with The Wellness
Choosing an assessment that fits the question
For a person who feels well and wants to understand long-term risk, an Lp(a) result may sit within a broader assessment. For someone with a previous abnormal report or a strong family history, a focused results consultation may be more useful than repeating a large panel without a purpose.
The Wellness's executive health assessment brings consultation, appropriate investigations and results review into one plan. The exact tests should reflect the history and clinical question. Health-check information describes available assessment routes; the team can confirm the appropriate scope and fee directly.
A good review explains what the result means, what it does not establish, which risks deserve attention and when the plan will be reviewed. It should not imply that a normal screen guarantees future health, or that ordering the largest number of tests is the same as better care.
New chest pain, severe breathlessness, collapse or sudden weakness or speech difficulty need urgent assessment, not a routine screening appointment. In the UK, call 999 for suspected heart attack or stroke. A favourable recent cholesterol or Lp(a) result does not make an acute symptom safe to ignore.
Frequently asked questions
Is lipoprotein(a) included in a normal cholesterol test?
Usually not. A standard lipid profile and Lp(a) are different measurements. The team can confirm whether Lp(a) is included in the proposed testing and whether it would add useful information for your history.
Can Lp(a) be raised when my LDL cholesterol is normal?
Yes. Lp(a) can add inherited cardiovascular risk that a routine lipid profile does not fully describe. A raised result should be interpreted with your other risk factors rather than treated as a diagnosis of blocked arteries.
Will diet and exercise lower my Lp(a)?
Lp(a) is largely determined by genes and is usually not substantially changed by lifestyle. Healthy habits still matter because they help address other cardiovascular risks, including blood pressure, weight and cholesterol.
Do I need an Lp(a) test every year?
Many people do not. Lp(a) is usually relatively stable, so an informative measurement may not need routine annual repetition. The doctor can decide whether a change in health or a specific clinical question justifies another test.
Should my family be tested if my result is high?
A raised result can be a reason to discuss assessment of close relatives, because Lp(a) is largely inherited. A lipid specialist or your usual clinician can advise which family members should be offered testing and how the findings would be used.
Does a raised Lp(a) mean I should stop my statin?
No. Statins do not lower Lp(a), but can reduce LDL and non-HDL cholesterol as part of lowering overall cardiovascular risk. Do not stop or change prescribed treatment without discussing your individual plan with the prescribing clinician.
Enquire about an Lp(a) assessment with The Wellness in London
This article provides general information and does not replace individual medical advice. Testing, interpretation, treatment and any referral depend on your clinical assessment.
Clinical sources
- American Heart Association: 2026 dyslipidaemia guideline summary, updated 13 March 2026.
- American Heart Association: Lp(a) and inherited cardiovascular risk.
- HEART UK: high lipoprotein(a), updated May 2026.
- MedlinePlus: lipoprotein(a) blood testing.
- The Wellness: executive health assessment in London.
- The Wellness: health-check options.